Premature Ejaculation (Male Health) Pipeline Forecast Report, H1, 2017 – Healthcare Pipeline Guide
Request Free Sample Report @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1070422
Premature ejaculation (PE) is also known as rapid ejaculation, is the most common type of sexual dysfunction in men. Ejaculation is controlled by the central nervous system. This happens when sexual stimulation and friction provide impulses that are delivered to the spinal cord and into the brain. The predisposing factors include erectile dysfunction, stress and certain medications that influence the action of chemical messengers in the brain (psychotropics) may contribute to premature ejaculation. Treatment includes topical anesthetic creams and antidepressants.
The Premature Ejaculation (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Premature Ejaculation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively.
Premature Ejaculation (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Market Research Hubs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Premature Ejaculation (Male Health).
- The pipeline guide reviews pipeline therapeutics for Premature Ejaculation (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Premature Ejaculation (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Premature Ejaculation (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Premature Ejaculation (Male Health)
Reasons to Buy:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Premature Ejaculation (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Premature Ejaculation (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Browse Full Report with TOC @ http://www.marketresearchhub.com/report/premature-ejaculation-pipeline-review-h1-2017-report.html
Table of Contents:
List of Tables
List of Figures
Market Research Hub Report Coverage
Premature Ejaculation - Overview
Premature Ejaculation - Therapeutics Development
Pipeline by Companies
Products under Development by Companies
Premature Ejaculation - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Premature Ejaculation - Companies Involved in Therapeutics Development
NeuroHealing Pharmaceuticals Inc
Plethora Solutions Holdings Plc
SK Chemicals Co Ltd
Premature Ejaculation - Drug Profiles
(lidocaine hydrochloride + prilocaine) - Drug Profile
Mechanism Of Action
IX-01 - Drug Profile
About Market Research Hub:
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
90 State Street,
Albany, NY 12207,
Toll Free: 866-997-4948 (US-Canada)
Follow Us on:
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Premature Ejaculation (Male Health) Pipeline Forecast Report, H1, 2017 – Healthcare Pipeline Guide here
News-ID: 556246 • Views: 507
More Releases from Pharmaceutical Research Reports [MRH]
Pipeline Analysis on Phenylalanine 4 Hydroxylase Reviewed by Company, Profiled D …
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 184.108.40.206) - Pipeline Review, H1 2017”. This research study outlays comprehensive information on the Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 220.127.116.11) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration
Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopepti …
According to the latest pipeline analysis, Aminopeptidase N (APN/CD13) acts as an exopeptidase and has been studied for decades. In recent years, it has been seen not only as a tumor-related target but also as a potential functional protein in various other physiological or pathological processes, such as analgesia, virus infection and inflammation. To elaborate further details on its global demand, a study titled “Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein
Global Indoleamine 2, 3 Dioxygenase 1 Industry Vital Pipeline Review for the Fir …
The indoleamine 2, 3 Dioxygenase 1 or IDO1 market is developing since the cancer treatment sector relies heavily on its’ in-depth research and high-quality treatments. Looking into this huge potential, a new study has been added to the vast online repository of Market Research Hub (MRH), with the title ‘’Indoleamine 2, 3 Dioxygenase 1 (Indoleamine Pyrrole 2, 3 Dioxygenase 1 or IDO1 or EC 18.104.22.168) - Pipeline Review, H1 2017‘’.
Prosthetic Joint Infections - Clinical Trials Rise Due to Higher Disease Inciden …
Market Research HUB's Pharmaceutical and Healthcare latest pipeline guide Prosthetic joint infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Prosthetic joint infections (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news
More Releases for Premature
Premature Ejacualtion Market - Global Outlook and Forecast to 2022
ReportsnReports.com adds "Premature Ejacualtion Market - Global Outlook and Forecast 2017 – 2022" report to its research store. The report considers the present scenario of the global premature ejaculation market and its in-depth analysis for the period 2017-2022. It includes a detailed study of growth drivers, trends, and restraints. The report also profiles the leading vendors in the market and other key vendors. Innovus Pharma, Plethora Solutions, Absorption Pharmaceuticals and Allergan are
Premature Ejaculation Treatment Market- Insights
Ejaculation means discharging of semen from the body. Premature ejaculation (PE) also known as rapid ejaculation, premature climax or early ejaculation is a condition in which the ejaculation happens earlier than a man or his partner would like during a sexual intercourse. The main sign of PE is incapability to delay ejaculation for more than one minute after penetration. Mainly PE can be classified in two types, namely lifelong (primary)
Topical Premature Ejaculation Market Likely to Witness High Growth
In terms of route of administration, the global premature ejaculation market can be classified into two segments: oral therapies and topical therapies. In 2016, the global oral PE drugs segment accounted for a major share of 75.72% of the global PE market, according to the recent report, Premature Ejaculation Market – Global Outlook and Forecast 2017 – 2022 published by Arizton Advisory and Intelligence. The report published states that the
Premature Labor (Tocolysis) - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Premature Labor (Tocolysis) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Premature Labor (Tocolysis) - Pipeline Review, H2 2017, provides an overview of the Premature Labor (Tocolysis) (Women's Health) pipeline landscape. Preterm labor or premature labor is defined as labor that begins before completion of 36
Premature Labor (Tocolysis) - Pipeline Review, H2 Market Research Report 2017
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Premature Labor (Tocolysis) - Pipeline Review, H2 2017”. Preterm labor or premature labor is defined as labor that begins before completion of 36 weeks of pregnancy. Symptoms include sensation of pelvic or lower abdominal pressure, mild abdominal cramps, diarrhea, vaginal spotting or bleeding and constant low, dull backache. Treatment includes corticosteroids and tocolytics. Request
Premature Labor (Tocolysis)-Market Insights, Epidemiology and Market Forecast-20 …
Market Research HUBs Premature Labor (Tocolysis) -Market Insights, Epidemiology and Market Forecast-2025 report provides an overview of the disease and in depth research related to Premature Labor (Tocolysis) for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Premature Labor (Tocolysis). It enables